Cargando…

Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study

BACKGROUND: Neoadjuvant chemotherapy (NAC) has evolved significantly and has been widely accepted for downstaging disease in early-stage and locally advanced breast cancer patients. Since the optimal surgical intervention for patients receiving NAC remains controversial, we aim to investigate the su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sang, Yuting, Zhou, Xujie, Chi, Weiru, Chen, Jiajian, Yang, Benlong, Hao, Shuang, Huang, Xiaoyan, Liu, Guangyu, Shao, Zhimin, Wu, Jiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647014/ https://www.ncbi.nlm.nih.gov/pubmed/36387082 http://dx.doi.org/10.3389/fonc.2022.984587

Ejemplares similares

Latissimus dorsi flap – the main force in breast reconstruction for breast tumor in Chinese population
por: Zheng, Shuyue, et al.
Publicado: (2023)

Immediate Breast Reconstruction After Neoadjuvant Chemotherapy: Factors Associated With Surgical Selection and Complications
por: Chi, Weiru, et al.
Publicado: (2023)

Treatment and survival outcomes in older women with primary breast cancer: A retrospective propensity score-matched analysis
por: Sang, Yuting, et al.
Publicado: (2022)

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC
por: Zheng, Shuyue, et al.
Publicado: (2022)

The Prognoses of Young Women With Breast Cancer (≤35 years) With Different Surgical Options: A Propensity Score Matching Retrospective Cohort Study
por: Li, Pei, et al.
Publicado: (2022)

Stabilization of CCDC102B by Loss of RACK1 Through the CMA Pathway Promotes Breast Cancer Metastasis via Activation of the NF-κB Pathway
por: Si, Jing, et al.
Publicado: (2022)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

Efficacy and Safety of Mitoxantrone Hydrochloride Injection for Tracing Axillary Sentinel Nodes in Breast Cancer: A Self-Controlled Clinical Trial
por: Jiao, Dechuang, et al.
Publicado: (2022)

Impact of Atypical Hyperplasia at Surgical Margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy
por: Su, An, et al.
Publicado: (2023)

Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy
por: Song, Yu-Chun, et al.
Publicado: (2023)

Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022)

Body composition change during neoadjuvant chemotherapy for breast cancer
por: Jang, Min Kyeong, et al.
Publicado: (2022)

Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Lu, Ying, et al.
Publicado: (2022)

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
por: Li, JunJie, et al.
Publicado: (2016)

The Role of Mammographic Calcification in the Neoadjuvant Therapy of Breast Cancer Imaging Evaluation
por: Li, Jun-jie, et al.
Publicado: (2014)

Case Report: A 3D-Printed Surgical Guide for Breast-Conserving Surgery After Neoadjuvant Chemotherapy
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Breast microbiome associations with breast tumor characteristics and neoadjuvant chemotherapy: A case-control study
por: Li, Xuejun, et al.
Publicado: (2022)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer
por: Truin, W., et al.
Publicado: (2015)

Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes
por: Adham, Sirin A., et al.
Publicado: (2022)

Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress
por: Chen, Yushi, et al.
Publicado: (2023)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

A Decision-Making Supporting Prediction Method for Breast Cancer Neoadjuvant Chemotherapy
por: Song, Dong, et al.
Publicado: (2021)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review
por: Zhao, Yueqiu, et al.
Publicado: (2022)

Contrast-enhanced ultrasonography for early prediction of response of neoadjuvant chemotherapy in breast cancer
por: Guo, Jiabao, et al.
Publicado: (2022)

Case of HER2neu+ Invasive Pleomorphic Lobular Carcinoma With Response to Conventional Neoadjuvant Chemotherapy: A Viable Option for an Exceedingly Rare Breast Cancer Type
por: Nelson, Blessie, et al.
Publicado: (2020)

An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine
por: Wang, Mozhi, et al.
Publicado: (2021)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

Mammographic density in relation to breast cancer recurrence and survival in women receiving neoadjuvant chemotherapy
por: Zdanowski, Anna, et al.
Publicado: (2023)

Machine Learning-Based Radiomics Nomogram Using Magnetic Resonance Images for Prediction of Neoadjuvant Chemotherapy Efficacy in Breast Cancer Patients
por: Chen, Shujun, et al.
Publicado: (2020)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Deep learning radiomic analysis of DCE-MRI combined with clinical characteristics predicts pathological complete response to neoadjuvant chemotherapy in breast cancer
por: Li, Yuting, et al.
Publicado: (2023)

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
por: Huang, Liang, et al.
Publicado: (2015)

The Type of Breast Reconstruction May Not Influence Patient Satisfaction in the Chinese Population: A Single Institutional Experience
por: Yang, Benlong, et al.
Publicado: (2015)

Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999−2017
por: Guo, Rong, et al.
Publicado: (2019)

Celecoxib may be a viable treatment option for breast cancer patients not treated with chemotherapy
por: Harris, Randall E., et al.
Publicado: (2022)

Risk factors of breast cancer recurrence in pathologic complete response achieved by patients following neoadjuvant chemotherapy: a single-center retrospective study
por: Choi, Joon Young, et al.
Publicado: (2023)

Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
por: Dai, Huijuan, et al.
Publicado: (2021)

Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor
por: Zheng, Chun-Hui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7qo9ndnqllf19sacjkn8rnvgkt